Professor of Law
Professor of Health Law, Bioethics and Human Rights
Professor Outterson teaches health law and corporate law at Boston University, where he co-directs the Health Law Program, currently ranked #2 in the country by US News. He serves as the editor-in-chief of the Journal of Law, Medicine & Ethics; faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section… Read more
Professor Outterson teaches health law and corporate law at Boston University, where he co-directs the Health Law Program, currently ranked #2 in the country by US News. He serves as the editor-in-chief of the Journal of Law, Medicine & Ethics; faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section on Law, Medicine & Health Care of the AALS; and a member of the Board of the American Society of Law, Medicine & Ethics. Before teaching, Professor Outterson was a partner at two major U.S. law firms.
His research work focuses on the organization and finance of the health sector. Areas of specialization include global pharmaceutical markets, particularly antibiotics and other antimicrobials that can degrade in usefulness over time through resistance. He leads an interdisciplinary project on the legal ecology of antimicrobial resistance, funded in part by the Robert Wood Johnson Foundation program on public health law. He is a faculty affiliate at the Harvard Center for Communicable Disease Dynamics and an appointed member of the Antimicrobial Resistance Working Group at the CDC.
Another significant body of work critiques access and equity issues created by global patent and drug regulation laws. Key texts in this debate include the WTO TRIPS Agreement and related trade agreements.
Professor Outterson publishes in both legal journals such as Yale Journal of Health Policy, Law & Ethics; Cardozo Law Review; University of Pittsburgh Law Review; Kansas Law Review and the American Journal of Law & Medicine as well as peer-reviewed medical and health policy journals such as New England Journal of Medicine; Health Affairs; Lancet Infectious Diseases; Environmental Philosophy; Medical Journal of Australia; Journal of Generic Medicines; Clinical Infectious Diseases; Journal of Law, and Medicine & Ethics. He blogs on health policy issues at www.theincidentaleconomist.com, which is one of the leading health economics blogs in the US.
On behalf of The New England Journal of Medicine and other clients, Outterson filed an amicus brief in the U.S. Supreme Court, supporting Vermont’s prescription privacy law. His work was cited by Justice Breyer in Sorrell v. IMS Health. A team led by Professors Outterson and Moncrieff at Boston University filed four amicus briefs supporting the Affordable Care Act, which was heard by the Court in the spring of 2012.
Outterson was recently appointed a Visiting Fellow at the Royal Institute of International Affairs in London, Chatham House where he will reside in Spring 2014, leading a working group at Chatham House on new business models to prevent antimicrobial resistance.
Science Magazine Kevin Outterson, School of Law This past January, microbiologists Kim Lewis and Slava Epstein reported the discovery of teixobactin, a compound that in lab dishes kills several antibiotic-resistant strains of bacteria. Media outlets heralded the discovery, announced in Nature, as a new solution to the growing problem of antimicrobial resistance… Expert quote: “For […]
New Scientist Kevin Outterson, School of Law A panel on antibiotics set up by the UK government says the world needs a global authority to pay drug companies to develop new antibacterial drugs… Expert quote: “This would be a very significant increase over existing funding levels.” View full article
Houston Chronicle Kevin Outterson, School of Law A clinical trial of an Ebola vaccine developed in part at the University of Texas Medical Branch in Galveston is vaccinating front-line health care workers in Sierra Leone, but researchers face a rapidly closing window to prove their case… Expert quote: “It’s kind of this sticky problem. If […]
MarketWatch Kevin Outterson, School of Law The White House last week issued the most extensive plan ever to fight drug-resistant bacteria, or superbugs, seeking to curb antibiotic use at farms and hospitals — and promote discovery of lethal bugs and antibiotics to kill them… Expert quote: “It is the boldest move against antibiotic resistance by […]
Wall Street Journal (subscription required) Kevin Outterson, School of Law The White House issued the most extensive action plan ever against drug-resistant bacteria, or superbugs, seeking to curb antibiotic use at farms and hospitals—and promote tests to find lethal bugs, and antibiotics to kill them… Expert quote: “It is the boldest move against antibiotic resistance […]
Vox Kevin Outterson, School of Law Antibiotic resistance — when bacteria outsmart the drugs we have to combat them — is a massive problem facing the modern world. While resistance to drugs is a natural evolutionary process, it’s been sped up by our overuse of antibiotics, spurring on more “superbug” infections, killing thousands of people […]
Vox Kevin Outterson, School of Law Scientists and public-health officials are a careful bunch who don’t often use terms like “nightmare,” “apocalypse,” and “catastrophe.”… Expert quote: “It’s almost unimaginable how going back to a pre-antibiotic era would affect US health care.” View full article
WBUR “CommonHealth” Kevin Outterson, School of Law You know the antibiotics issue is really getting serious when even the biggest fast food chain in the world gets on the bandwagon — joining the president of the United States, among a great many others… View full article quoting expert Kevin Outterson
Vox Kevin Outterson, School of Law Antibiotic-resistant bacteria have become a massive health problem, killing thousands of people every year and prompting calls to phase out the unnecessary use of the drugs on farm animals and in people… Expert quote: “These consumer-driven approaches are the most feasible way to reduce the US use of animal […]
Motherboard Kevin Outterson, School of Law As a global community, we’re in a high-stakes race against rapidly developing antibiotic resistance—and we’re losing… Expert quote: “There are a dozen cancer therapies that are more than $100,000 for a course of treatment, despite very modest proof of efficacy. Meanwhile a course of new antibiotics costs something like […]